Short Interest in enVVeno Medical Corporation (NASDAQ:NVNO) Drops By 16.0%

enVVeno Medical Corporation (NASDAQ:NVNO) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 447,400 shares, a decrease of 16.0% from the February 28th total of 532,700 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average trading volume of 127,600 shares, the short-interest ratio is presently 3.5 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Maven Securities LTD bought a new position in shares of enVVeno Medical during the 3rd quarter worth about $295,000. Geode Capital Management LLC grew its stake in enVVeno Medical by 7.8% during the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after buying an additional 10,902 shares during the last quarter. Hohimer Wealth Management LLC acquired a new stake in shares of enVVeno Medical in the third quarter valued at $286,000. Westside Investment Management Inc. raised its stake in shares of enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. Finally, Fermata Advisors LLC lifted its holdings in enVVeno Medical by 18.1% during the 4th quarter. Fermata Advisors LLC now owns 35,706 shares of the company’s stock worth $108,000 after buying an additional 5,481 shares in the last quarter. Institutional investors own 34.71% of the company’s stock.

enVVeno Medical Stock Performance

NASDAQ NVNO traded down $0.09 on Thursday, reaching $2.50. The company’s stock had a trading volume of 65,684 shares, compared to its average volume of 107,480. The stock has a market cap of $43.84 million, a PE ratio of -1.94 and a beta of 1.38. enVVeno Medical has a twelve month low of $2.45 and a twelve month high of $6.48. The firm’s 50 day moving average is $3.14 and its two-hundred day moving average is $3.29.

enVVeno Medical (NASDAQ:NVNO) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Equities research analysts anticipate that enVVeno Medical will post -1.32 EPS for the current fiscal year.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).